Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer

1Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-49. doi: 10.3322/caac.21660 Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A et al Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2021 71 209 49 10.3322/caac.2166033538338Open DOISearch in Google Scholar

2Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023-75. doi: 10.1016/S0140-6736(17)33326-3 Allemani C Matsuda T Di Carlo V Harewood R Matz M Nikšić M et al Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries Lancet 2018 391 1023 75 10.1016/S0140-6736(17)33326-3587949629395269Open DOISearch in Google Scholar

3Zadnik V, Žagar T, Tomšič S, Lokar K, Duratović Konjević A, Zakotnik B. [Survival of cancer patients]. [Slovenian]. Ljubljana; Institute of Oncology; 2020 Zadnik V Žagar T Tomšič S Lokar K Duratović Konjević A Zakotnik B [Survival of cancer patients]. [Slovenian] Ljubljana Institute of Oncology 2020Search in Google Scholar

4Montagne F, Guisier F, Venissac N, Baste JM. The role of surgery in lung cancer treatment: present indications and future perspectives – state of the art. Cancers 2021; 13: 1-24. doi: 10.3390/cancers13153711 Montagne F Guisier F Venissac N Baste JM The role of surgery in lung cancer treatment: present indications and future perspectives – state of the art Cancers 2021 13 1 24 10.3390/cancers13153711834519934359612Open DOISearch in Google Scholar

5Remon J, Soria JC, Peters S. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol 2021; 32: 1637-42. doi: 10.1016/J.ANNONC.2021.08.1994 Remon J Soria JC Peters S Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy Ann Oncol 2021 32 1637 42 10.1016/J.ANNONC.2021.08.199434481037Open DOISearch in Google Scholar

6Shukla N, Hanna N. Neoadjuvant and adjuvant immunotherapy in early-stage non-small cell lung cancer. Lung Cancer Targets Ther 2021; 12: 51-60. doi: 10.2147/LCTT.S277717 Shukla N Hanna N Neoadjuvant and adjuvant immunotherapy in early-stage non-small cell lung cancer Lung Cancer Targets Ther 2021 12 51 60 10.2147/LCTT.S277717825392234234606Open DOISearch in Google Scholar

7The National Lung Screening Trial Research Team. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med 2011; 365: 395-409. doi: 10.1056/NEJMOA1102873/SUPPL_FILE/NEJMOA1102873_DISCLOSURES.PDF The National Lung Screening Trial Research Team Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening N Engl J Med 2011 365 395 409 10.1056/NEJMOA1102873/SUPPL_FILE/NEJMOA1102873_DISCLOSURES.PDFOpen DOISearch in Google Scholar

8de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 2020; 382: 503-13. doi: 10.1056/nejmoa1911793 de Koning HJ van der Aalst CM de Jong PA Scholten ET Nackaerts K Heuvelmans MA et al Reduced lung-cancer mortality with volume CT screening in a randomized trial N Engl J Med 2020 382 503 13 10.1056/nejmoa1911793Open DOISearch in Google Scholar

9Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer. J Thorac Oncol 2016; 11: 39-51. doi: 10.1016/j.jtho.2015.09.009 Goldstraw P Chansky K Crowley J Rami-Porta R Asamura H Eberhardt WEE et al The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer J Thorac Oncol 2016 11 39 51 10.1016/j.jtho.2015.09.00926762738Open DOISearch in Google Scholar

10Taber S, Pfannschmidt J. Validation of the 8th lung cancer TNM classification and clinical staging system in a German cohort of surgically resected patients. Innov Surg Sci 2020; 5: 1-9.doi: 10.1515/iss-2020-0010 Taber S Pfannschmidt J Validation of the 8th lung cancer TNM classification and clinical staging system in a German cohort of surgically resected patients Innov Surg Sci 2020 5 1 910.1515/iss-2020-0010779830133506088Open DOISearch in Google Scholar

11Cai B, Fulcher N, Boyd M, Spira A. Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: a real-world retrospective observational study. Thorac Cancer 2021; 12: 2055-64. doi: 10.1111/1759-7714.14007 Cai B Fulcher N Boyd M Spira A Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: a real-world retrospective observational study Thorac Cancer 2021 12 2055 64 10.1111/1759-7714.14007828701034028984Open DOISearch in Google Scholar

12Abrão FC, Moreira FR, de Abreu IRLB, Marciano MG, Younes RN. Real-life long-term cohort of patients with stage IIIA non-small-cell lung cancer: overall survival related to patients’ characteristics and multiple treatment models. JCO Glob Oncol 2021; 7: 1572-85. doi: 10.1200/go.21.00219 Abrão FC Moreira FR de Abreu IRLB Marciano MG Younes RN Real-life long-term cohort of patients with stage IIIA non-small-cell lung cancer: overall survival related to patients’ characteristics and multiple treatment models JCO Glob Oncol 2021 7 1572 85 10.1200/go.21.00219861334934797696Open DOISearch in Google Scholar

13Thomas DC, Arnold BN, Rosen JE, Salazar MC, Detterbeck FC, Blasberg JD, et al. The significance of upfront knowledge of N2 disease in non-small cell lung cancer. World J Surg 2018; 42: 161-71. doi: 10.1007/s00268-017-4165-6 Thomas DC Arnold BN Rosen JE Salazar MC Detterbeck FC Blasberg JD et al The significance of upfront knowledge of N2 disease in non-small cell lung cancer World J Surg 2018 42 161 71 10.1007/s00268-017-4165-628799084Open DOISearch in Google Scholar

14Yun JK, Bok JS, Lee GD, Kim HR, Kim YH, Kim DK, et al. Long-term outcomes of upfront surgery in patients with resectable pathological N2 non-small-cell lung cancer. Eur J Cardio-Thoracic Surg 2020; 58: 59-69. doi: 10.1093/ejcts/ezaa042 Yun JK Bok JS Lee GD Kim HR Kim YH Kim DK et al Long-term outcomes of upfront surgery in patients with resectable pathological N2 non-small-cell lung cancer Eur J Cardio-Thoracic Surg 2020 58 59 69 10.1093/ejcts/ezaa04232155245Open DOISearch in Google Scholar

15Crinò L, Weder W, van Meerbeeck J, Felip, ESMO Guidelines Working Group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v103-15. doi: 10.1093/annonc/mdq207 Crinò L Weder W van Meerbeeck J Felip ESMO Guidelines Working Group Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2010 21Suppl 5 v103 15 10.1093/annonc/mdq20720555058Open DOISearch in Google Scholar

16Vansteenkiste J, De Ruysscher D, Eberhardt WEE, Lim E, Senan S, Felip E, et al.; ESMO Guidelines Working Group. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl 6:) vi89-98. doi: 10.1093/annonc/mdt241 Vansteenkiste J De Ruysscher D Eberhardt WEE Lim E Senan S Felip E et al ESMO Guidelines Working Group. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 2013 24 Suppl 6 vi89–98 10.1093/annonc/mdt24123860613Open DOISearch in Google Scholar

17Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-14. doi: 10.1097/JTO.0b013e31812f3c1a Goldstraw P Crowley J Chansky K Giroux DJ Groome PA Rami-Porta R et al The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours J Thorac Oncol 2007 2 706 14 10.1097/JTO.0b013e31812f3c1a17762336Open DOISearch in Google Scholar

18Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 2014; 25: 1681-90. doi: 10.1093/annonc/mdu145 Kerr KM Bubendorf L Edelman MJ Marchetti A Mok T Novello S et al Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer Ann Oncol 2014 25 1681 90 10.1093/annonc/mdu14524718890Open DOISearch in Google Scholar

19Heineman DJ, Beck N, Wouters MW, van Brakel TJ, Daniels JM, Schreuers WH, et al. The dutch national clinical audit for lung cancer: a tool to improve clinical practice? An analysis of unforeseen ipsilateral mediastinal lymph node involvement in the Dutch Lung Surgery Audit (DLSA). Eur J Surg Oncol 2018; 44: 830-4. doi: 10.1016/J.EJSO.2017.12.002 Heineman DJ Beck N Wouters MW van Brakel TJ Daniels JM Schreuers WH et al The dutch national clinical audit for lung cancer: a tool to improve clinical practice? An analysis of unforeseen ipsilateral mediastinal lymph node involvement in the Dutch Lung Surgery Audit (DLSA) Eur J Surg Oncol 2018 44 830 4 10.1016/J.EJSO.2017.12.00229396329Open DOISearch in Google Scholar

20Debevec L, Jerič T, Kovač V, Bitenc M, Sok M. Is there any progress in routine management of lung cancer patients? A comparative analysis of an institution in 1996 and 2006. Radiol Oncol 2009; 43: 47-53. doi: 10.2478/V10019-009-0008-X Debevec L Jerič T Kovač V Bitenc M Sok M Is there any progress in routine management of lung cancer patients? A comparative analysis of an institution in 1996 and 2006. Radiol Oncol 2009 43 47 53 10.2478/V10019-009-0008-XOpen DOISearch in Google Scholar

21Zwitter M, Čufer T, Vrankar M, Kern I, Štupnik T, Rozman A, et al. Lung Cancer in Slovenia. J Thorac Oncol 2019; 14: 1327-31. doi: 10.1016/J.JTHO.2019.02.025 Zwitter M Čufer T Vrankar M Kern I Štupnik T Rozman A et al Lung Cancer in Slovenia J Thorac Oncol 2019 14 1327 31 10.1016/J.JTHO.2019.02.025Open DOISearch in Google Scholar

22Tas F, Ciftci R, Kilic L, Karabulut S. Age is a prognostic factor affecting survival in lung cancer patients. Oncol Lett 2013; 6: 1507-13. doi: 10.3892/ol.2013.1566 Tas F Ciftci R Kilic L Karabulut S Age is a prognostic factor affecting survival in lung cancer patients Oncol Lett 2013 6 1507 13 10.3892/ol.2013.1566381357824179550Open DOISearch in Google Scholar

23Visbal AL, Williams BA, Nichols FC, Marks RS, Jett JR, Aubry MC, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004; 78: 209-15. doi: 10.1016/J.ATHORACSUR.2003.11.021. Visbal AL Williams BA Nichols FC Marks RS Jett JR Aubry MC et al Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002 Ann Thorac Surg 2004 78 209 15 10.1016/J.ATHORACSUR.2003.11.021Open DOISearch in Google Scholar

24Saw SPL, Zhou S, Chen J, Lai G, Ang MK, Chua K, et al. Association of clinicopathologic and molecular tumor features with recurrence in resected early-stage epidermal growth factor receptor-positive non-small cell lung cancer. JAMA Netw Open 2021; 4: e2131892. doi: 10.1001/jamanetworko-pen.2021.31892 Saw SPL Zhou S Chen J Lai G Ang MK Chua K et al Association of clinicopathologic and molecular tumor features with recurrence in resected early-stage epidermal growth factor receptor-positive non-small cell lung cancer JAMA Netw Open 2021 4 e2131892 10.1001/jamanetworko-pen.2021.31892Open DOISearch in Google Scholar

25Ramlau R, Cufer T, Berzinec P, Dziadziuszko R, Olszewski W, Popper H, et al. Epidermal growth factor receptor mutation-positive non-small-cell lung cancer in the real-world setting in Central Europe: the INSIGHT study. J Thorac Oncol 2015; 10: 1370-4. doi: 10.1097/JTO.0000000000000621 Ramlau R Cufer T Berzinec P Dziadziuszko R Olszewski W Popper H et al Epidermal growth factor receptor mutation-positive non-small-cell lung cancer in the real-world setting in Central Europe: the INSIGHT study J Thorac Oncol 2015 10 1370 4 10.1097/JTO.000000000000062126291014Open DOISearch in Google Scholar

26Ryska A, Berzinec P, Brcic L, Cufer T, Dziadziuszko R, Gottfried M, et al. NSCLC molecular testing in Central and Eastern European countries. BMC Cancer 2018; 18: 269. doi: 10.1186/s12885-018-4023-4 Ryska A Berzinec P Brcic L Cufer T Dziadziuszko R Gottfried M et al NSCLC molecular testing in Central and Eastern European countries BMC Cancer 2018 18 269 10.1186/s12885-018-4023-4584518429523116Open DOISearch in Google Scholar